Achievement of Proteinuria Targets ≤0.4 g/g in Lupus Nephritis: A Post Hoc Analysis of the AURORA 1 Study of Voclosporin (EULAR 2025) - Mar 30, 2025 - Abstract #POS1334; I220; Pres time: Jun 14, 2025; 10:15 AM - 11:45 AM; Location: Poster Area; "The 52-week, Phase 3 AURORA 1 study showed that the addition of voclosporin to low-dose glucocorticoids and mycophenolate mofetil (MMF) led to significantly greater and earlier reductions in proteinuria compared to treatment with low-dose glucocorticoids and MMF alone [7]...Participants were randomized to either voclosporin (23.7 mg) or matching placebo (control) twice daily, in combination with MMF (target 2 g/day) and low-dose glucocorticoids (intravenous methylprednisolone on Days 1 and 2 [total 1 g], followed by oral prednisone at a starting dose of 20-25 mg/day, tapered to ≤2.5 mg/day by Week 16)... Nearly half of the AURORA 1 population achieved a UPCR ≤0.4 g/g at least once during the 52-week study, surpassing treatment targets recommended by current guidelines for the management of LN. A greater proportion of participants treated with voclosporin achieved UPCR ≤0.4 g/g and did so significantly earlier than control-treated participants, with comparable rates..."
Retrospective data • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
M. Dall'Era 1; B. H. Rovin 2; S. Almaani 2; L. Hodge 3; V. Birardi 3; E. Yap 3
|